Napredna pretraga

Pregled bibliografske jedinice broj: 889867

Cortisol in schizophrenia : No association with tobacco smoking, clinical symptoms or antipsychotic medication


Nedić Erjavec, Gordana; Uzun, Suzana; Nikolac Perković, Matea; Kozumplik, Oliver; Švob Strac Dubravka; Mimica, Ninoslav; Hirasawa-Fujita, Mika; Domino, Edward F.; Pivac, Nela
Cortisol in schizophrenia : No association with tobacco smoking, clinical symptoms or antipsychotic medication // Progress in neuro-psychopharmacology & biological psychiatry, 77 (2017), 228-235 doi:10.1016/j.pnpbp.2017.04.032 (međunarodna recenzija, članak, znanstveni)


Naslov
Cortisol in schizophrenia : No association with tobacco smoking, clinical symptoms or antipsychotic medication

Autori
Nedić Erjavec, Gordana ; Uzun, Suzana ; Nikolac Perković, Matea ; Kozumplik, Oliver ; Švob Strac Dubravka ; Mimica, Ninoslav ; Hirasawa-Fujita, Mika ; Domino, Edward F. ; Pivac, Nela

Izvornik
Progress in neuro-psychopharmacology & biological psychiatry (0278-5846) 77 (2017); 228-235

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Antipsychotic medication ; Caucasians ; Chlorpromazine equivalent doses ; Cigarette smoking ; Nicotine addiction ; Salivary cortisol ; Schizophrenia ; Schizophrenia symptoms

Sažetak
Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30 ± 26.68 years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00 AM, 90–120 min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses. Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers.Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness.The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
HRZZ-IP-2014-09-4289 - Genomski i glikanski biomarkeri PTSP-a (Nela Pivac, )

Ustanove
Institut "Ruđer Bošković", Zagreb,
Klinika za psihijatriju Vrapče,
Medicinski fakultet, Osijek

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati